Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207218> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4387207218 endingPage "e322" @default.
- W4387207218 startingPage "e322" @default.
- W4387207218 abstract "To report on the utilization of dose-escalated radiotherapy, acute toxicities, and survival following definitive proton therapy (PT) for osteosarcoma patients in a prospective multi-institutional study.Data on patients with osteosarcoma treated with definitive intent PT were queried from the Proton Collaborative Group (PCG) prospective registry. A similar query was performed on an institutional database with IRB approval. Overall survival rates were calculated by Kaplan-Meier. Toxicities were scored using CTCAE v4.0.Forty osteosarcoma patients across 9 institutions received definitive intent PT between 2011-2021 and met the eligibility criteria. Median age was 32 years (Range: 6-86 years). Median PT dose was 66.6 GyRBE (Range: 50.4-80.0 GyRBE); 38 patients received proton therapy alone, whereas 2 received combined proton/photon therapy. Seventeen (42.5%) patients received doses ≥70 GyRBE. Median follow-up was 3.1 years (Range: 0.9-10.5 years). One-year and three-year overall survival rates were 83.5% and 59.1%, respectively, with 14 deaths due to disease. Excluding skin desquamation and alopecia, 22 patients (55.0%) developed any acute grade 2+ toxicity, and 5 patients (12.5%) developed any grade 3 toxicities. No acute grade 4-5 toxicities were reported. The most frequent grade 2+ non-skin toxicities were fatigue (37.5%), anorexia/weight loss (17.5%), mucositis/esophagitis (22.5%), pain (20.0%), and nausea/vomiting (10.0%). The most frequent grade 3 toxicities were anorexia/weight loss (5.0%), mucositis/esophagitis (5.0%), and neurologic symptoms (5.0%).In this multi-institutional study, 42.5% of osteosarcoma patients treated with PT received doses between 70-80 Gy, with 12.5% experiencing any grade 3 toxicity. Long-term outcomes for disease control, late toxicity, and quality-of-life are needed to more fully assess the benefits and risks of dose-escalated radiotherapy in this radioresistant tumor. The authors plan to assess the outcomes of osteosarcoma patients treated with dose-escalated radiotherapy for unresectable or gross residual disease in future studies." @default.
- W4387207218 created "2023-09-30" @default.
- W4387207218 creator A5001252838 @default.
- W4387207218 creator A5005973513 @default.
- W4387207218 creator A5009839688 @default.
- W4387207218 creator A5028634314 @default.
- W4387207218 creator A5029710197 @default.
- W4387207218 creator A5032895490 @default.
- W4387207218 creator A5040258679 @default.
- W4387207218 creator A5043792798 @default.
- W4387207218 creator A5046597561 @default.
- W4387207218 creator A5046881923 @default.
- W4387207218 creator A5052573263 @default.
- W4387207218 creator A5061226372 @default.
- W4387207218 creator A5062492688 @default.
- W4387207218 creator A5067352155 @default.
- W4387207218 creator A5067536094 @default.
- W4387207218 creator A5076008987 @default.
- W4387207218 creator A5078180311 @default.
- W4387207218 date "2023-10-01" @default.
- W4387207218 modified "2023-10-17" @default.
- W4387207218 title "Multi-Institutional Experience of Proton Therapy for Osteosarcoma in the Proton Collaborative Group (PCG) Prospective Registry" @default.
- W4387207218 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2363" @default.
- W4387207218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785149" @default.
- W4387207218 hasPublicationYear "2023" @default.
- W4387207218 type Work @default.
- W4387207218 citedByCount "0" @default.
- W4387207218 crossrefType "journal-article" @default.
- W4387207218 hasAuthorship W4387207218A5001252838 @default.
- W4387207218 hasAuthorship W4387207218A5005973513 @default.
- W4387207218 hasAuthorship W4387207218A5009839688 @default.
- W4387207218 hasAuthorship W4387207218A5028634314 @default.
- W4387207218 hasAuthorship W4387207218A5029710197 @default.
- W4387207218 hasAuthorship W4387207218A5032895490 @default.
- W4387207218 hasAuthorship W4387207218A5040258679 @default.
- W4387207218 hasAuthorship W4387207218A5043792798 @default.
- W4387207218 hasAuthorship W4387207218A5046597561 @default.
- W4387207218 hasAuthorship W4387207218A5046881923 @default.
- W4387207218 hasAuthorship W4387207218A5052573263 @default.
- W4387207218 hasAuthorship W4387207218A5061226372 @default.
- W4387207218 hasAuthorship W4387207218A5062492688 @default.
- W4387207218 hasAuthorship W4387207218A5067352155 @default.
- W4387207218 hasAuthorship W4387207218A5067536094 @default.
- W4387207218 hasAuthorship W4387207218A5076008987 @default.
- W4387207218 hasAuthorship W4387207218A5078180311 @default.
- W4387207218 hasConcept C126322002 @default.
- W4387207218 hasConcept C141071460 @default.
- W4387207218 hasConcept C188816634 @default.
- W4387207218 hasConcept C2778496288 @default.
- W4387207218 hasConcept C2779134260 @default.
- W4387207218 hasConcept C2779920096 @default.
- W4387207218 hasConcept C2780580376 @default.
- W4387207218 hasConcept C2780852908 @default.
- W4387207218 hasConcept C43270747 @default.
- W4387207218 hasConcept C509974204 @default.
- W4387207218 hasConcept C71924100 @default.
- W4387207218 hasConceptScore W4387207218C126322002 @default.
- W4387207218 hasConceptScore W4387207218C141071460 @default.
- W4387207218 hasConceptScore W4387207218C188816634 @default.
- W4387207218 hasConceptScore W4387207218C2778496288 @default.
- W4387207218 hasConceptScore W4387207218C2779134260 @default.
- W4387207218 hasConceptScore W4387207218C2779920096 @default.
- W4387207218 hasConceptScore W4387207218C2780580376 @default.
- W4387207218 hasConceptScore W4387207218C2780852908 @default.
- W4387207218 hasConceptScore W4387207218C43270747 @default.
- W4387207218 hasConceptScore W4387207218C509974204 @default.
- W4387207218 hasConceptScore W4387207218C71924100 @default.
- W4387207218 hasIssue "2" @default.
- W4387207218 hasLocation W43872072181 @default.
- W4387207218 hasLocation W43872072182 @default.
- W4387207218 hasOpenAccess W4387207218 @default.
- W4387207218 hasPrimaryLocation W43872072181 @default.
- W4387207218 hasRelatedWork W1496967564 @default.
- W4387207218 hasRelatedWork W2013903839 @default.
- W4387207218 hasRelatedWork W2065134328 @default.
- W4387207218 hasRelatedWork W2072404698 @default.
- W4387207218 hasRelatedWork W2088425824 @default.
- W4387207218 hasRelatedWork W2100269289 @default.
- W4387207218 hasRelatedWork W2243375749 @default.
- W4387207218 hasRelatedWork W2729406632 @default.
- W4387207218 hasRelatedWork W2767101348 @default.
- W4387207218 hasRelatedWork W3092250922 @default.
- W4387207218 hasVolume "117" @default.
- W4387207218 isParatext "false" @default.
- W4387207218 isRetracted "false" @default.
- W4387207218 workType "article" @default.